Standard BioTools Inc
NASDAQ:LAB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.9216
1.68
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Standard BioTools Inc
Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.
Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.
Revenue: Q1 2025 revenue was $40.8 million, down 10% year-over-year and in line with expectations.
Guidance Maintained: Full year 2025 revenue guidance remains unchanged at $165 million to $175 million, with revenue expected to be weighted more toward the second half of the year.
Cost Reductions: Non-GAAP operating expenses decreased by 22% year-over-year, driven by $10 million in additional cost reductions this quarter, bringing total annualized savings since the SomaLogic merger to $90 million.
Gross Margin: Non-GAAP gross margin was 53.2%, down from 56.2% last year, mainly due to lower volumes and product mix.
Cash Position: Ended Q1 with $261 million in cash and equivalents and no material debt, with significantly reduced cash burn versus last year.
Instrument Sales: Instrument revenue grew 24% year-over-year in Q1, led by continued success of the Hyperion XTi platform.
Academic Headwinds: Mid-teens percentage decline expected in Americas academic revenue, with ongoing academic funding delays and spending curbs.
M&A Focus: Management confirms a disciplined M&A approach, noting a robust pipeline of potential deals but high standards for execution.
